Background: Traditional animal models in preclinical pharmacology show limited predictive accuracy for human outcomes due to interspecies differences, contributing to high drug attrition rates and ethical concerns. Recent regulatory changes have pushed the development of alternative, human-centered methods.Objective: To comprehensively investigate and evaluate novel non-animal approaches for establishing pharmacological safety and efficacy, such as organ-on-a-chip technologies, in vitro systems, and in silico models.Methods: A narrative evaluation of existing literature was conducted, concentrating on the technological principles, pharmacological applications, predictive performance, and regulatory acceptance of alternative testing strategies.Results: Compared with traditional 2D cultures, advanced in vitro models such as 3D organoids and iPSC-derived cells exhibit greater physiological relevance. Rapid, economical, and high-throughput predictions are made possible by in silico methods such as QSAR, PBPK modeling, and AI-based technologies. With improved translational fidelity, organ-on-a-chip technologies mimic the dynamic microenvironments of human organs. Strong, mechanism-based safety assessment frameworks are produced by integrated testing procedures that combine these methods. But there are still issues with scalability, validation, and standards.Conclusion: With growing regulatory approval for their future application, the incorporation of alternative approaches signifies a paradigm change toward more ethical, human-centered, and predictive drug development.